XML 31 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
INTANGIBLE ASSETS (Details) (USD $)
9 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Sep. 30, 2013
ResearchMember
Sep. 30, 2013
PatentsMember
Sep. 30, 2013
DrugMember
Sep. 30, 2013
PharmaceuticalMember
Sep. 30, 2013
PatentedTechnologyMember
Sep. 30, 2013
IntangibleassetsMember
Dec. 31, 2012
Cato Research discounted contract [Member]
Dec. 31, 2011
Cato Research discounted contract [Member]
Dec. 31, 2010
Cato Research discounted contract [Member]
Dec. 31, 2012
Patents for the AzoneTS-based product candidates and formulation [Member]
Dec. 31, 2011
Patents for the AzoneTS-based product candidates and formulation [Member]
Dec. 31, 2010
Patents for the AzoneTS-based product candidates and formulation [Member]
Dec. 31, 2012
Drug Master Files containing formulation, clinical and safety documentation used by the FDA [Member]
Dec. 31, 2011
Drug Master Files containing formulation, clinical and safety documentation used by the FDA [Member]
Dec. 31, 2010
Drug Master Files containing formulation, clinical and safety documentation used by the FDA [Member]
Dec. 31, 2013
In-process pharmaceutical products for 2 indications [Member]
Dec. 31, 2011
In-process pharmaceutical products for 2 indications [Member]
Dec. 31, 2010
In-process pharmaceutical products for 2 indications [Member]
Dec. 31, 2012
Technology related intangible assets [Member]
Dec. 31, 2011
Technology related intangible assets [Member]
Dec. 31, 2010
Technology related intangible assets [Member]
Finite-Lived Intangible Assets [Line Items]                                                  
Estimated Life         3 years 4 years 6 months 4 years 6 months 4 years 6 months     3 years     6 years     6 years     6 years          
Cost $ 9,980,000       $ 355,000 $ 1,305,000 $ 1,500,000 $ 6,820,000 $ 9,625,000 $ 9,980,000 $ 355,000                            
Accumulated Amortization 355,000 355,000     355,000             355,000 355,000                                
Total 9,625,000 9,625,000 9,625,000 9,625,000    1,305,000 1,500,000 6,820,000 9,625,000 9,625,000          1,305,000 1,305,000 1,305,000 1,500,000 1,500,000 1,500,000 6,820,000 6,820,000 6,820,000 9,625,000 9,625,000 9,625,000
Estimated amortization expense                                                  
2013                                                   
2014                                                   
2015 1,069,000                                                
2016 2,139,000                                                
2017 $ 2,139,000